Studies
FREQUENCY OF SELECTED SINGLE NUCLEOTIDE POLYMORPHISMS IN PHASE WITH THE MUTANT AND WILD-TYPE HTT ALLELES IN HUNTINGTON DISEASE GENE EXPANSION CARRIERS (WE45491)
Neurology
Adult Subjects
A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSONS DISEASE
Neurology
Adult Subjects
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease
Activate
Neurology
Adult Subjects
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, BIOMARKERS, AND EFFICACY OF TOMINERSEN IN INDIVIDUALS WITH PRODROMAL AND EARLY MANIFEST HUNTINGTONS DISEASE
Neurology
Adult Subjects
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease
Parkinsons Foundation PD GENEration Genetic Registry
Neurology
Adult Subjects
Female Subjects
Male Subjects